Pharmaceutical Product Development Income Statement
View: Annual | Quarterly
This data is provided as per license from EDGAR Online
| Dec 07 | Dec 06 | Dec 05 | |
|---|---|---|---|
| Revenue | 1,414.5 | 1,247.7 | 1,037.1 |
| Cost of Goods Sold | 771.6 | 670.5 | 543.3 |
| Gross Profit | 642.9 | 577.2 | 493.8 |
| Gross Profit Margin | 45.4% | 46.3% | 47.6% |
| SG&A Expense | 357.3 | 309.4 | 258.9 |
| Depreciation & Amortization | 55.6 | 47.7 | 40.3 |
| Operating Income | 230.0 | 220.0 | 194.6 |
| Operating Margin | 16.3% | 17.6% | 18.8% |
| Nonoperating Income | 18.3 | 16.0 | 4.2 |
| Nonoperating Expenses | 0.3 | 0.5 | 1.1 |
| Income Before Taxes | 247.9 | 235.5 | 197.7 |
| Income Taxes | 84.6 | 78.8 | 66.3 |
| Net Income After Taxes | 163.4 | 156.7 | 131.5 |
| Continuing Operations | 163.4 | 156.6 | 131.5 |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 163.4 | 156.6 | 131.5 |
| Total Net Income | 163.4 | 156.6 | 131.5 |
| Net Profit Margin | 11.6% | 12.6% | 12.7% |
| Diluted EPS from Total Net Income ($) | 1.36 | 1.32 | 0.41 |
| Dividends per Share | 0.19 | 0.10 | 0.03 |
This data is provided as per license from EDGAR Online
